^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Mucosal Melanoma |
| Drug: | Loqtorzi (toripalimab-tpzi) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Adjuvant anti-PD-1 ab (Toripalimab) versus high-dose IFN-a2b in resected mucosal melanoma: A phase ? randomized trial.
Published date:
05/19/2021
Excerpt:
Mucosal melanoma pts...PDL-1positive 51.0%(CPS≥1%, 22C3), PDL-1 negative 49.0%....Toripalimab shows longer RFS in PDL1 (+) subgroup and better tolerance than HDI.
DOI:
10.1200/JCO.2021.39.15_suppl.9573
Trial ID:
